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Abstract
There is an urgent need to develop new and effective agents for cancer targeting. In this work, a multivalent antibody is
characterized in vivo in living animals. The antibody, termed ‘‘trimerbody’’, comprises a single-chain antibody (scFv)
fragment connected to the N-terminal trimerization subdomain of collagen XVIII NC1 by a flexible linker. As indicated by
computer graphic modeling, the trimerbody has a tripod-shaped structure with three highly flexible scFv heads radially
outward oriented. Trimerbodies are trimeric in solution and exhibited multivalent binding, which provides them with at
least a 100-fold increase in functional affinity than the monovalent scFv. Our results also demonstrate the feasibility of
producing functional bispecific trimerbodies, which concurrently bind two different ligands. A trimerbody specific for the
carcinoembryonic antigen (CEA), a classic tumor-associated antigen, showed efficient tumor targeting after systemic
administration in mice bearing CEA-positive tumors. Importantly, a trimerbody that recognizes an angiogenesis-associated
laminin epitope, showed excellent tumor localization in several cancer types, including fibrosarcomas and carcinomas.
These results illustrate the potential of this new antibody format for imaging and therapeutic applications, and suggest that
some laminin epitopes might be universal targets for cancer targeting.
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Introduction
An optimized antibody fragment designed for targeting cancer
in vivo should fulfill several requirements: high specificity and
affinity for the target antigen, low immunogenicity; and be ready
available form expression to purified protein [1]. The pharmaco-
kinetic properties of the antibody should be adjusted depending on
the intended use. Format and molecular weight of tumor targeting
antibodies are critical factors that influence their pharmacokinet-
ics. Intact IgG molecules (150 kDa) display low blood clearance
and incomplete tumor penetration. On the other hand, small
monovalent single-chain variable fragments (scFv) (25–30 kDa) are
more effective in tumor penetration but they are cleared too
rapidly and have poor tumor retention because of their binding
properties [2].
The ideal tumor-targeting antibodies are intermediate-sized
multivalent molecules, which provide rapid tissue penetration,
high target retention and rapid blood clearance. Recent
biodistribution studies [3] indicate that bivalent antibodies such
as diabodies (60 kDa), and minibodies (80 kDa) may be best suited
for tumor imaging and therapy due to a higher total tumor uptake
and better tumor-to-blood ratios than intact IgG molecules.
Diabodies are non-covalent dimeric molecules spontaneously
formed in scFv with short linkers connecting the variable region
genes [4,5]. Another useful format derived from scFv, with
expanded half-life but still rapid, high-level uptake into tumors is
the minibody, which results from the fusion of scFv with the IgG1
CH3 domain, which provokes dimerization [6].
However, despite of the good results obtained with these
engineered formats in various models [3,7–12], there are still some
limitations that need to be dealt with in order to take full
advantage of the targeting capability of these recombinant
antibodies. One of these drawbacks is their relatively limited
flexibility, and the necessity of the second antigen to be precisely
oriented and located in a strictly defined area once the antibody
binds the first antigen [13,14]. Therefore, bound antigens should
be almost opposed in the diabody, and in a small circular area in
the minibody, which actually precludes the binding to the second
antigen in a number of situations. This implies that part of the
increased affinity observed relies mainly on binding/rebinding,
and not on simultaneous binding to different molecules of the
antigen. To circumvent these drawbacks we have developed a new
class of multivalent antibodies. These antibodies, termed ‘‘trimer-
bodies’’, use the N-terminal association subdomain of collagen
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collagen alpha chains, to drive multimerization [15].
Until now, most of the tumor targeting agents have focused on
tumor-associated cell surface markers, such as the carcinoem-
bryonic antigen (CEA). The CEA is a heavily glycosylated cell
adhesion molecule that is widely used as marker for colorectal,
stomach, pancreas, breast, and lung carcinomas; and several other
carcinomas of epithelial origin [16]. However, molecules, which
are selectively expressed in the stroma and in angiogenesis-active
sites, appear to be particularly suited for antibody-based strategies
for targeting solid tumors. During tumor progression, the
extracellular matrix suffers extensive remodeling through deposi-
tion of new components and proteolytic degradation, giving rise to
unique epitopes not usually accessible in homeostatic organs [17].
In the present study, we characterized the binding affinity in vitro
and the in vivo tumor targeting properties of trimerbodies with
specificity for human CEA, and an angiogenesis-associated
laminin epitope. A trimerbody with specificity for the hapten
NIP (4-hydroxy-5-iodo-3-nitrophenyl) was used as control. All the
purified trimerbodies exhibited excellent antigen binding capacity
and were multivalent, which provides them with a significant
increase in functional affinity. Fluorescently labeled anti-CEA
trimerbodies showed efficient tumor targeting of colorectal
carcinomas in mice, and importantly, anti-laminin trimerbodies
showed excellent tumor localization in several cancer types,
including fibrosarcomas and carcinomas. These results illustrate
the potential of this novel antibody format for imaging and
therapeutic applications.
Materials and Methods
Antibodies and Reactives
The monoclonal antibodies (mAbs) used included 9E10
(Abcam, Cambridge, UK) specific for human c-myc, and
NCRC23 (AbD Serotec, Kidlington, UK) specific for human
CEA. The polyclonal antibodies, a rabbit anti-bovine serum
albumin (BSA), a horseradish peroxidase (HRP)-conjugated goat
anti-rabbit IgG, and an HRP-conjugated goat anti-mouse IgG (Fc
specific) were from Sigma-Aldrich (St. Louis, MO, USA). Laminin
extracted from the Engelbreth-Holm-Swarm (EHS) mouse tumor
was from Becton Dickinson Labware (Bedford, MA, USA).
Human CEA and BSA were from Sigma-Aldrich. BSA was
conjugated with 4-hydroxy-5-iodo-3-nitrophenyl (NIP) (Sigma-
Aldrich) in a molar ratio of 10: 1 (NIP10-BSA) as described [18].
Cells and culture conditions
HEK-293 cells (human embryo kidney epithelia; CRL-1573),
and its derivative 293T cells (CRL-11268), HT-1080 (human
fibrosarcoma; CCL-121), MKN45 cells (human stomach adeno-
carcinoma; JCRB-0254), and HeLa cells (human cervix carcino-
ma; CCL-2) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (vol/vol) heat-inactivated Fetal
Calf Serum (FCS) (all from Invitrogen, Carlsbad, CA) referred as
to DMEM complete medium (DCM). HeLa
CEA cells [19] were
grown in DCM supplemented with 750 mg/ml G418 (Invitrogen).
Construction of expression vectors
pCR3.1-L36 and pCR3.1-L36-NC1
ES- expression vectors were
constructed as described [17,20]. The plasmid pVOM1.C23
containing the MFE-23 (anti-human CEA) scFv gene was kindly
provided by Dr. R. E. Hawkins (University of Manchester, UK).
The MFE-23 expression cassette was subcloned as HindIII-NotI
into the vector pCEP4.6xHis-myc [20], resulting in pCEP4-MFE-
23. Plasmid pCEP4-B1.8 containing the B1.8 (anti-hapten NIP)
scFv gene and the polyhistidine and c-myc epitopes was
constructed as described [20]. To construct the plasmids
pCEP4-MFE-23-NC1
ES- and pCEP4-B1.8-NC1
ES- the 252 bp
NotI fragment derived from the plasmid pCR3.1-L36-NC1
ES- was
ligated into the NotI digested backbone of plasmids pCEP4-MFE-
23 or pCEP4-B1.8 respectively.
Cell transfections and purification of recombinant
antibodies
HEK-293 or 293T cells were transfected with the appropriate
expression vectors, using Superfect (QIAGEN GmbH, Hilden,
Germany). To generate stable cell lines, pCR3.1-L36, and
pCR3.1-L36-NC1
ES- transfected HEK-293 cells were selected in
DCM with 500 mg/ml G418; pCEP4-MFE-23-NC1
ES- and
pCEP4-B1.8-NC1
ES- transfected HEK-293 cells were selected in
DCM with 150 mg/ml hygromycin B (Invitrogen). Supernatants
from transient and stable transfected cell populations were
analyzed for protein expression by ELISA, SDS-PAGE and
Western blotting using anti-myc mAb. Stable transfected HEK-
293 cells were used to collect serum-free conditioned media
medium (,1 liter) was concentrated (610) with a 10.000 MWCO
Vivaflow 50 filter (Vivascience AG, Hannover, Germany),
dialyzed against PBS (pH 7.4) and loaded onto a HisTrap HP
1 ml column using an A ¨KTA Prime plus system (GE Healthcare,
Uppsala, Sweden). The purified antibodies were dialyzed against
PBS, analyzed by SDS-PAGE under nonreducing or reducing
conditions, and stored at 220uC.
Analytical gel filtration chromatography
Experiments were performed at room temperature with an
A ¨KTA FPLC system (GE Healthcare) using a Superdex 200 10/
300GL column in PBS. Samples of 100 ml at a concentration of
0.5–1.0 mg/ml were injected and eluted at a flow rate of 0.5 ml/
min. The column was calibrated with blue dextran (excluded
volume) and molecular weight markers from 16 to 655 kDa (GE
Healthcare).
ELISA
The ability of purified trimerbodies (L36, MFE23, or B1.8) to
bind murine laminin, human CEA, or NIP10-BSA conjugates was
studied by ELISA as described [21]. The multivalence of
trimerbody molecules was studied by ELISA using supernatant
from single (pCR3.1-L36-NC1
ES- or pCEP4-B1.8-NC1
ES-) and
double (pCR3.1-L36-NC1
ES- and pCEP4-B1.8-NC1
ES-) transfect-
ed 293T cells. Maxisorp (NUNC Brand Products, Roskilde,
Denmark) plates were coated with laminin (0.5 mg/well), and after
washing and blocking with 200 ml 5% non-fat dry milk in PBS,
100 ml of supernatant from single or double transfected 293T cells
were added for 1 hour at room temperature. After three washes,
100 ml of NIP10-BSA (10 mg/ml) were added for 1 hour at room
temperature. After three washes, 100 ml of rabbit anti-BSA
antibody (1:1000) in 0.05% Tween-20-PBS were added for 1 hour
at room temperature. After three more washes 100 ml of HRP-
conjugated goat anti-rabbit IgG were added for 1 hour at room
temperature, after which the plate was washed and developed.
Flow Cytometry
The expression of CEA on HeLa, and HeLa
CEA cells and the
binding of recombinant antibodies was studied as described [22].
Briefly, cells were incubated with anti-CEA mAb (5 mg/ml) or
purified trimerbodies (anti-NIP or anti-CEA, 10 mg/ml) and mAb
9E10 (4 mg/ml) in 100 ml for 45 min. After washing, the cells were
treated with appropriate dilutions of FITC-conjugated goat anti-
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EPICS XL (Coulter Electronics, Hialeah, FL, USA).
Surface plasmon resonance analysis
Analyses were performed at room temperature using a BIAcore
3000 (GE Healthcare). CM5 dextran sensor chips (GE Healthcare)
were used in all analyses, with HBS-EP running buffer (0.01 M
HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% Surfactant
P20), which was filtered with a 0.22 mm filter and degassed before
use. Proteins were dissolved in 10 mM sodium acetate, pH 4.5.
NIP10-BSA was directly immobilized on the sensor chip surface as
recommended in the BIAapplications Handbook (GE Healthcare),
in independent flow cells at approximately 100, 1800 and 8500
resonance units (RU). BSA was immobilized at 1900 on reference
flow cell. After each experiment, surfaces were regenerated with
30 mM HCl, allowing resonance signals to return to baseline
values. Analyses were performed in duplicate.
For kinetic analyses, a flow cell with small amounts of
immobilized NIP10-BSA (,100 RU) was used to minimize mass
transport effects and rebinding. Individual samples consisting of
purified scFv or trimerbody were passed over the chip surface at a
flow rate of 20 ml/min and association/dissociation was measured.
Bulk refractive index changes were removed by subtracting the
reference flow cell responses; the average response of a blank
injection was also subtracted from all sensorgrams. Data were
analyzed using BIAevaluation v4.1 software provided with the
biosensor, and kinetic data were fitted to the Langmuir 1:1
interaction model.
Molecular Modeling
The structure of the binding domain (L36 scFv) was modeled by
comparative modeling [23] using as template the structure of
2GHW.B from the Protein Data Bank (PDB) [24]. This template
was obtained with blast [25] e-value 2e-79 and a 70% of identity.
The structure of the N-terminal trimerization domain of murine
collagen XVIII NC1 was obtained from ModBase [26]. Both
domains were linked by a 21 amino acid long peptide forming the
L36 trimerbody monomer. The coordinates of the other two
monomers were obtained applying a three-fold rotation axis
symmetry. The trimer was formed by merging the coordinates of
the three monomers. The structure of the trimer was optimized
with GROMACS [27] and its energy was evaluated with DFIRE
[28]. In order to compare the values of DFIRE between the
monomer and the trimer, the energies were normalized dividing
them by the length of the sequence.
Serum stability
To determine whether trimerbody constructs remained func-
tional in serum, five hundred nanograms of purified L36
trimerbody were incubated in 12.5% mouse serum from BALB/
c mice (Harlan Ibe ´rica, Barcelona, Spain) at 37uC for up to 72 h.
Samples were removed for analysis at 3 h, 24 h, and 72 h
following the start of incubation and frozen until the entire study
was completed. As a control, a second set of serum-exposed
samples was frozen immediately to represent a zero time point.
Trimerbodies were then tested for their capability to retain
functional binding to murine laminin by ELISA.
Antibody labeling with cyanine 5
Purified L36 scFv and trimerbodies were labeled with cyanine 5
(Cy5) NHS esters (GE Healthcare) according to the manufactur-
er’s recommendations. Cy5-labeled recombinant antibodies were
separated from unincorporated Cy5 dye by gel-filtration on
Sephadex G25-M (PD-10 Columns, GE Healthcare), and
concentrated in 10.000 MWCO Vivaspin 500 filter (Vivascience)
to approximately 1 mg/ml. The labeling ratio of Cy5 to antibody
(Cy5:antibody) was calculated as described [29] and was close to
1:1. The functionality of Cy5-labeled antibodies was verified by
ELISA against specific antigen.
Infrared immunophotodetection in tumor-bearing mice
Wild-type MKN45, HT1080, or HeLa cells (1–2610
6) were
implanted subcutaneously (n=4) into the dorsal space of 6-week-
old female Hsd: Athymic Nude-Foxn1
nu mice (Harlan Ibe ´rica).
Nodule dimensions were used to calculate tumor volume using the
formula: width
26length60.52. When tumors reached an appro-
priate volume (0.2–0.4 cm
3), mice were injected in the tail vein
with 100 ml Cy5-labeled antibody solution in PBS (5 mg/Kg).
Mice were imaged using the high-resolution charge-coupled-
device (CCD) cooled digital camera ORCA-2BT (Hamamatsu
Photonics France, Massy, France), and Wasabi software (Hama-
matsu Photonics), under anesthesia. All mice were handled in
accordance with the guidelines of the Hospital Universitario
Puerta de Hierro Animal Care and Use Committee and
performed in accordance with Spanish legislation.
Results
Design and Expression of Trimerbody Constructs
Structural analysis of the NC1 domainof collagen XVIII suggests
that it consists of three segments, an N-terminal trimerization
domain implicated in self-assembly of homotrimers; a central
protease-sensitive hinge region; and the compact C-terminal
endostatin domain [30]. We have previously shown that an
engineered antibody containing the anti-laminin L36 scFv and
the N-terminal trimerization domain of murine collagen XVIII
NC1 was produced in human 293 cells in a functional active form
[15]. To provide sufficient spatial flexibility to the N-terminal scFv a
twenty-one amino acid artificial linker was used ([15], and Fig. S1).
The trimeric nature of the purified scFv-NC1 fusion was
demonstrated by ultracentrifugation [15] and analytical gel
filtration chromatography (Fig. 1A). The elution of L36 scFv in
an analytical gel filtration shows that it is monomeric. The
calibration of the column using the markers yields a molecular
weight of 24.2 kDa, in good agreement with the theoretical one
(26.9 kDa). By contrast, the elution of L36 scFv-NC1 fusion
corresponds to an estimated MW of 109.3 kDa, indicating that it is
a trimer (the theoretical mass of the trimer is 111.4 kDa), in
agreement with the previously reported analysis by analytical
ultracentrifugation [15]. This trimeric antibody format was
designated ‘‘trimerbody’’.
In this study, we have extended the concept by designing
trimerbodies with specificity for the hapten NIP or CEA. The scFv
genes derived from the anti-NIP B1.8 [18] and the anti-CEA
MFE-23 [31] antibodies were similarly assembled and expressed
as soluble secreted proteins in human HEK293 cells and purified
from conditioned medium by immobilized metal affinity chroma-
tography. The purification scheme yielded antibodies that were
.95% pure by SDS–PAGE (data not shown). Both B1.8 and
MFE-23 trimerbodies eluted from the column as single peaks (data
not shown) comparable to that shown in Figure 1A.
Antigen Binding Activity
The functionality of purified trimerbodies was demonstrated by
ELISA against plastic immobilized NIP-BSA conjugates (NIP10-
BSA), murine EHS laminin, and human CEA (Fig. 1B). Their
ability to detect the antigen in a cellular context was investigated
Antibodies for Cancer Imaging
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CEA on the cell surface. Fluorescence staining was observed after
incubation with MFE-23 trimerbody, followed by reaction with
anti-myc mAb and detection with FITC-conjugated goat anti-
mouse antibodies. In contrast, incubation of CEA-positive cells
with B1.8 trimerbody or incubation of CEA-negative HeLa cells
with MFE-23 trimerbody revealed no staining (Fig. 1C). These
results demonstrated that trimerbodies recognized not only
immobilized antigen, but also native antigen on the surface of
tumor cells.
Surface plasmon resonance (SPR) was used to determine the
influence of the scFv and trimerbody formats on B1.8 antibody
function.Wecomparedthebindingcurvesforeachantibodyformat
using three different densities of NIP10-BSA covalently bound to the
chip surface. Dextran-coupled BSA was used in a reference flow
cell. To compare binding responses during association and
dissociation, several concentrations of purified B1.8 antibodies were
injected, ranging from 9 to 1,200 nM for B1.8 scFv and from 6 to
800 nM for B1.8 trimerbody onto the NIP10-BSA (1900 RU)
surface (data not shown). In these conditions, only the trimerbody
approached saturation of the antigen surface, whereas the scFv
bound slowly and showed more rapid apparent dissociation.
Sensorgrams indicated that the trimeric antibody has greater
binding capacity than its monovalent counterpart (Fig. 1D).
For kinetic analyses, a flow cell coated with ,100 RU of NIP10-
BSA was used. In these assays, the B1.8 scFv had a profile
Figure 1. Molecular characterization of purified trimerbodies. (A) Elution profile of the gel filtration experiment of L36 constructs (scFv and
scFv-NC1 ‘‘trimerbody’’). The exclusion (Ve) and total (VT) volumes are indicated. The elution volumes of selected molecular weight markers are also
indicated with arrows and the corresponding molecular weights. For the shake of clarity the absorbance of both chromatograms have been scaled
and shifted in the figure. The functionality of purified trimerbodies was demonstrated by ELISA (B) against plastic immobilized BSA, murine EHS
laminin, NIP-BSA conjugates (NIP10-BSA), and human CEA; and by flow cytometry analysis (C) on CEA-negative and CEA-positive tumor cells. Isotype
control (filled histogram), anti-CEA trimerbody (solid line), and anti-NIP trimerbody (dotted line) are shown. (D) Analysis of B1.8 scFv and B1.8
trimerbody binding to NIP10-BSA using BIAcore. The curves showed data obtained after subtraction of the binding response to a BSA-coated
reference surface (1900 RU), to remove the effects of non-specific binding. Representative sensorgrams corresponding to the adjusted binding curves
of affinity-purified B1.8 scFv and B1.8 trimerbody (dil. 1200, and 800 nM) in buffer HBS-EP injected over the same two flow cells as above. Antibody
samples and running buffer were injected over the surfaces (5 min, flow rate 20 ml/min) and the dissociation phase was monitored for 8 min.
doi:10.1371/journal.pone.0005381.g001
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slower association and faster dissociation rates. The kinetic rate
constants for association (ka) and dissociation (kd) were determined
by simultaneous fitting (global fitting) using the Langmuir 1:1
interaction model. For B1.8 scFv, the apparent association and
dissociation rate constants were ka 1.0610
461.7610
2 M
21 s
21
and kd 2610
2364610
25 s
21 (Chi2=0.189). Using KD=k d/ka,
the equilibrium dissociation constant for B1.8 scFv was estimated
as 2610
27 M. Depending on the antibody concentration tested in
each cycle, the trimerbody injected onto the low surface density of
NIP10-BSA could probably bind both mono- and multivalently,
and the apparent kinetic binding constants might include avidity
effects of multivalent binding. Using a 1:1 interaction model in
which association and dissociation phases were treated separately
for each concentration, we also fitted the experimental results for
trivalent B1.8 binding. Data from curves with resonance levels that
approach Rmax would be close to those obtained for monovalent
binding. In this case, as the concentration of trimerbody B1.8
increased, the calculated ka diminished from 4610
5 M
21 s
21
(12.5 nM trimerbody) to 2610
4 M
21 s
21 (800 nM trimerbody).
These changes are compatible with changes in the proportion of
antibody that binds the ligand mono- or multivalently, since
approaching surface saturation leads to a larger proportion of
monovalent antibody binding. The apparent kd had narrower
range, from 6610
24 (12.5 nM) to 9610
24 (800 nM). Considering
that at 12.5 nM, most of the trimerbody can bind bi- or
multivalently, the functional affinity of the trimerbody calculated
from this concentration could be KD=1.5610
29 M or higher.
To further assess that at least two antigen-binding sites were
located on the same trimerbody molecule, 293T cells were
transfected with plasmid encoding L36 trimerbody, B1.8 trimer-
body or cotransfected with both plasmids. Western blot analysis
showed that the amount of trimerbody was higher in double-
transfected than in single-transfected 293T cells (data not shown).
Conditioned media from single-transfected 293T cells bound
NIP10-BSA or laminin, whereas conditioned media from double-
transfected 293T cells recognized both antigens (Fig. 2A). In
sandwich ELISA, conditioned medium from double-transfected
293T was added to laminin-coated wells and, after washing, the
laminin-bound trimerbodies were able to capture soluble NIP10-
BSA (Fig. 2B). Trimerbodies in the supernatant from 293T cells
single-transfected with plasmid encoding L36 trimerbody were
shown to bind to laminin, but the bound trimerbody did not
capture, in turn, NIP10-BSA.
Stability in vitro
Testing the stability of engineered antibody fragments in serum
is critical to determine their potential application in vivo.W e
therefore determined the functionality of L36 trimerbody after
incubation in mouse and human serum at 37uC for prolonged
periods of time. As shown in Fig. 3, L36 trimerbody retained 80–
90% of its binding activity after 72 hours of incubation.
Tumor Targeting
To evaluate the tissue distribution and tumor targeting of anti-
NIP, anti-CEA and anti-laminin trimerbodies we used an optical
molecular imaging system, which allows a kinetic evaluation of
tumor targeting and antibody clearance in the same animal
imaged at different time points. Trimerbodies were labeled with
the near-infrared fluorochrome Cy5 and injected in the tail vein of
nude mice bearing MKN45 (stomach adenocarcinoma), HT-1080
Figure 2. Binding activities of monospecific and bispecific
trimerbody molecules. Supernatant from single-transfected [pEGFP-
N1, pCR3.1-L36-NC1
ES-, or pCEP4-B1.8-NC1
ES-] 293T cells are compared
with supernatant from double-transfected [pCR3.1-L36-NC1
ES- and
pCEP4-B1.8-NC1
ES-] 293T cells by direct ELISA (A), using plates coated
with BSA, NIP-BSA conjugates (NIP10-BSA), and murine EHS laminin; and
by sandwich-ELISA (B) using plates coated with laminin.
doi:10.1371/journal.pone.0005381.g002
Figure 3. Serum stability of trimerbody molecules. Purified L36
trimerbody was incubated in human or mouse serum at 37uC, as
explained in material and methods, and the reaction mixtures were
analyzed by ELISA.
doi:10.1371/journal.pone.0005381.g003
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xenografts (n=4/group). All trimerbodies showed a rapid renal
clearance after i.v. injection, with peak signal intensity at 3 h and
no detectable bladder signal at 48 h postinjection (Fig. 4A and C).
Elimination of the L36-Cy5 scFv was even more rapid, and
fluorescence was not detected in the bladder 24 hours after
injection (Fig. 4C).
The control B1.8 trimerbody showed no detectable localization
in any of the three tumor types studied (Fig. 4B and 5A). A strong
and selective accumulation in CEA-positive tumors was observed
in the case of the MFE-23 trimerbody. After i.v. injection of
MFE23-Cy5 trimerbody, maximum tumor uptake was detected at
3 h, whereas the signal intensity decreased by 24 h and remained
detectable for at least 48 h (Fig. 4B). The anti-laminin trimerbody
showed localization in all the tumors studied, although the kinetics
of signal onset differed from that observed with anti-CEA
trimerbodies (Fig. 4B and 5). Maximum tumor uptake was at
24 h, which was lower than that of the MFE-23 trimerbody. The
anti-laminin scFv also showed specific tumor uptake but at a much
lower level that of the anti-laminin trimerbody (Fig. 4B and 4D).
Discussion
Our previous studies showed the ability of collagen-derived
sequences to promote antibody trimerization [15]. We reported
that fusion of the N-terminal association subdomain of collagen
XVIII NC1, responsible for the non-covalent trimerization of
collagen XVIII alpha chains, to the C-terminus of a scFv antibody
confers a trimeric state to the fused antibody (‘‘trimerbody’’).
Using a scFv (L36) that recognizes an angiogenesis-associated
laminin epitope [21] and inhibits tumor angiogenesis and growth
[20], we demonstrated that locally produced trimeric L36 was
more effective than its monomeric counterparts in blocking
capillary morphogenesis in vitro, and in preventing tumor growth
in vivo [15]. Recently, another group [32] has used a similar
approach to drive antibody multimerization. They demonstrated
that a short collagen-like peptide scaffold was able to promote
trimerization of fused scFv fragments (‘‘collabody’’).
In this study, we present the most comprehensive characterization
to date (both in vitro and in vivo)o ft h ea n t i b o d y - N C 1f u s i o n ,a n dw e
extend the concept by making analogous molecules with specificity
Figure 4. Targeting of fluorescently labeled antibodies to CEA-positive human tumor xenografts in nude mice. Near-infrared
fluorescence imaging of nude mice bearing dorsal subcutaneous (s.c.) MKN45 human gastric-carcinoma tumors. Ventral (A, C) and dorsal (B, D)
imaging was performed at 3, 24, and 48 hours after intravenous (i.v.) injection with Cy5-labeled trimerbodies (A, B), or Cy5-labeled L36 scFv (C, D). b:
bladder, t: tumor.
doi:10.1371/journal.pone.0005381.g004
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All the trimerbodies were isolated in functional active form from
conditioned medium of transfected HEK293 cells and easily purified
using immobilized metal affinity chromatography. Purified trimer-
bodies are trimeric in solution, and exhibit excellent antigen binding
capacity and stability. Trimerbodies are very efficient recognizing
antigen when immobilized, or associated to the tumor cell surface.
SPR analysis demonstrated that the trimerbody had a higher binding
signal than the monomeric antibody and apparently slower
dissociation, consistent with multivalent binding to the antigen. We
calculated that the anti-NIP trimerbody has at least a 100-fold
increase in apparent functional affinity for NIP-BSA conjugates
compared to its monovalent counterpart. This result suggests that this
affinity gain might be conferred by avidity effects of a second
combining site in the trimerbody molecule. The presence of at least
two functional binding sites in one single trimerbody molecule was
further demonstrated in bispecific trimerbodies. Stable bifunctional
anti-laminin x anti-NIP trimerbodies were easily produced by the
coexpression of two different trimerbody constructs in human cells.
The gain in affinity through avidity makes trimerbodies
attractive for in vivo imaging as an alternative reagent to dimeric
antibodies. It is tempting to speculate that trimerbodies will be
preferred over dimeric antibodies (diabodies and minibodies),
although this property may be dependent on the structure and
density of the antigen recognized by the scFv modules. For full
avidity in multivalent antibodies targeted to surface-bound
molecules, the antigen binding sites must point out towards the
same direction. If simultaneous multiple binding is not sterically
possible, then apparent gains in functional affinity are likely to be
small and due only to the effect of increased rebinding, which is
dependent on diffusion rates and surface antigen concentration
[33]. Analysis of the trimerbody model suggests a tripod-shaped
structure with the scFv domains outward oriented (Fig. 6).
Flexibility between antigen binding sites is another important
aspect in the design of multivalent antibodies required to cross-link
surface receptors on either the same or adjacent cells [2]. The
twenty-one residue linker, with a maximal length of 79.8 A ˚ if the
conformation is fully extended [34], is very flexible allowing
numerous binding geometries. When an antigen-antibody inter-
action takes place the possibility of establishing a second
interaction depends on the valence, orientation and flexibility of
the antigen-binding site. Multiple binding can effectively reduce
the off rates thereby increasing the retention time of the antibody
bound to the target antigen. In this respect, a major advantage of
trimerbody over other trimeric formats (e.g. collabody) is the
flexibility. The more compact/rigid collabody structure reduces
accessibility of the scFv modules [15], that is a critical parameter
for tumor targeting in vivo.
Thus, multimerization of scFv contructs has advantages for in
vivo applications. Multivalent recombinant antibodies, such as
diabodies and minibodies have shown promise as in vivo targeting
agents [2]. Trimerbodies are intermediate-sized, multivalent
molecules that exhibit high stability under physiological condi-
tions. The potential of trimerbody molecules for in vivo targeting
was assessed in nude mice bearing human tumor xenografts. Anti-
CEA trimerbody localized rapidly and specifically to CEA-positive
Figure 5. Targeting of fluorescently labeled trimerbodies to CEA negative human tumor xenografts in nude mice. Near-infrared
fluorescence imaging of nude mice bearing s.c. HT1080 human fibrosarcoma tumors (A) or HeLa human cervical adenocarcinoma tumors (B). Imaging
was performed at 3, 24, and 48 hours after i.v. injection with Cy5-labeled trimerbodies.
doi:10.1371/journal.pone.0005381.g005
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3 hours postinjection and slowly washed out over time. Fluores-
cence was still detectable in the tumor at 48 hours after
trimerbody injection. Importantly, the anti-laminin L36 trimer-
body localized in all the tumors studied independently of tumor
type. Maximum tumor uptake of anti-laminin trimerbodies was at
24 h following administration. Although the anti-laminin L36 scFv
showed specific tumor accumulation, the tumor uptake was
limited, probably due to the rapid clearance from the blood pool
(with half-lives less than 15 min) and its monovalent nature
(involving low retention times) [35–38].
According to our previous results, the L36 epitope is located in
the middle part of the rod-like portion of the laminin long arm, in
a highly flexible area, which corresponds to a protease-susceptible
site [39]. We have postulated that this epitope is only exposed
during basement membrane (BM) assembly [39], where polymer-
izing intact laminin acts as a scaffold for the recruitment of other
BM components [40]. The restricted expression of this epitope, to
situations associated with BM remodeling, would explain the
slower tumor uptake of L36 trimerbodies compared with
trimerbodies targeting tumor-associated antigens, and the reduced
renal uptake of L36 anti-laminin trimerbodies compared with
other anti-laminin antibodies in the literature [41].
Beyond its diagnostic applications, trimerbodies offer promising
therapeutic opportunities on the basis of the selective delivery of
bioactive molecules to the target tissue. Some of the immediate
applications of trimerbodies specific for tumor-associated antigens
(e.g. human epidermal growth factor receptor 2, prostate-specific
antigen) or targeting tumor stroma (e.g., fibroblast activation
protein) and neovasculature (e.g VEGFR-2/KDR or fibronectin
extra-domain B) include the development of fusion proteins with
angiogenic inhibitors [15], cytokines, enzymes, or truncated
receptors, and conjugation with radionuclides [42].
Supporting Information
Figure S1 Schematic structure of the scFv-NC1 gene (trimer-
body).
Found at: doi:10.1371/journal.pone.0005381.s001 (0.13 MB TIF)
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